Related Experiment Video
Updated: Oct 13, 2025
Primary Microglia Isolation from Mixed Glial Cell Cultures of Neonatal Rat Brain Tissue
Published on: August 15, 2012
Propofol Inhibits Microglial Activation via miR-106b/Pi3k/Akt Axis
Jianhui Liu1, Pu Ai2, Yiyan Sun1
1Department of Anesthesiology, Tongji Hospital Affiliated to Tongji University School of Medicine, Shanghai, China.
Abstract:
Propofol is an established intravenous anesthetic agent with potential neuroprotective effects. In this study, we investigated the roles and the underlying mechanisms of propofol in inhibiting the pro-inflammatory responses of microglia. Propofol significantly reduced the messenger RNA (mRNA) levels of Tnf, Nos2, and NF-κB pathway related genes Ticam1, Myd88, Irf3, and Nfkb1 in lipopolysaccharide (LPS)-treated primary microglia. After screening the miRNA profiles in microglia under LPS and propofol treatment conditions, we found propofol abrogated the LPS-induced misexpression of miRNAs including miR-106b, miR-124, miR-185, and miR-9. Perturbation of function approaches suggested miR-106b as the core miRNA that mediated the anti-inflammatory effects of propofol on microglial activation. RNA sequencing (RNA-seq) analysis further identified Pi3k/Akt signaling as one of the most affected pathways after miR-106b perturbation of function. The treatment of Pi3k/Akt signaling agonist 740Y-P elevated miR-106b-reduced Akt phosphorylation and abolished the inhibitory effects of miR-106b on the pro-inflammatory responses of microglia. Our results suggest propofol inhibits microglial activation via miR-106b/Pi3k/Akt axis, shedding light on a novel molecular mechanism of propofol-mediated immunomodulatory effects and implying propofol as potential therapeutics for treating neuroinflammation-related neurodegenerative diseases.
Insights
Propofol reduces inflammation in brain immune cells (microglia) by regulating specific microRNAs and the Pi3k/Akt pathway. This reveals a novel mechanism for propofol
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Propofol is an anesthetic with potential neuroprotective properties.
- Microglia play a key role in neuroinflammation.
- Understanding propofol's effects on microglia is crucial for neurodegenerative disease research.
Purpose of the Study:
- To investigate the mechanisms by which propofol inhibits pro-inflammatory responses in microglia.
- To identify key molecular players, including microRNAs, involved in propofol's anti-inflammatory actions.
Main Methods:
- Primary microglia were treated with lipopolysaccharide (LPS) and propofol.
- Messenger RNA (mRNA) and microRNA (miRNA) profiles were analyzed.
- Functional assays and RNA sequencing (RNA-seq) were performed to elucidate signaling pathways.
Main Results:
- Propofol significantly reduced inflammatory gene mRNA levels (Tnf, Nos2) and NF-κB pathway genes.
- Propofol counteracted LPS-induced changes in specific miRNAs, notably miR-106b.
- miR-106b was identified as a key mediator, acting via the Pi3k/Akt signaling pathway.
Conclusions:
- Propofol inhibits microglial activation through the miR-106b/Pi3k/Akt signaling axis.
- This study uncovers a novel molecular mechanism for propofol's immunomodulatory effects.
- Propofol shows potential as a therapeutic agent for neuroinflammation-associated neurodegenerative diseases.
